Ribaxamase

Drug Profile

Ribaxamase

Alternative Names: Kymerase; P3A; SYN 004; Synthetic Bacillus licheniformis isoenzyme - Synthetic Biologics

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Ipsat Therapies
  • Developer Synthetic Biologics
  • Class Aminohydrolases; Anti-infectives
  • Mechanism of Action Beta lactamase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Clostridium infections; Diarrhoea

Most Recent Events

  • 05 Jan 2017 Top-line safety and efficacy data from phase-IIb trial in Clostridium infections (Prevention) released by Synthetic Biologics
  • 01 Nov 2016 Synthetic Biologics completes a phase II trial for Clostridium infections (Prevention) in USA, Bulgaria and Poland (NCT02563106)
  • 06 Oct 2016 Synthetic Biologics receives other grant from Centers for Disease Control and Prevention for ribaxamase development in Clostridium infections (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top